Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong ...
As of October 22, 2024, the average one-year price target for Cullinan Therapeutics is $33.37/share. The forecasts range from a low of $28.28 to a high of $42.00. The average price target represents ...
Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cullinan Management (CGEM – Research Report) and VYNE Therapeutics (VYNE – Research Report) with bullish ...
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results